Enfortumab Vedotin Reactions Reclassified as TEC, Not TEN
A JAAD analysis published October 12, 2026 reclassifies severe enfortumab vedotin cutaneous reactions as TEC rather than TEN, with implications for management and drug continuation.
Topic
Cutaneous Adverse Events
Topic